ARPA-H, FWIW, is setup within the NIH. But it is structured to focus on more of "breakthrough" type processes, procedures, devices etc. Also the ARPA-H proposals are not driven solely by peer-review scoring unlike most NIH funding mechanisms. Typically ARPA-H tends to me across specific disease areas and more general in nature

>> What is the mandate of ARPA-H as compared to NIH?

ARPA-H has a much more commercial/translational focus, much like DARPA